Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 8/20 | 0.38 |
| ▸ | ACHE | P22303 | 8/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1330181 | 0.92 | C5AR1 (0.42) | C5AR1BCHEACHEHTTSMN1; SMN2 | |
| SCHEMBL1329386 | 0.91 | CD274 (0.39) | C5AR1BCHEACHEHTTSMN1; SMN2 | |
| SCHEMBL1328126 | 0.90 | CD274 (0.42) | C5AR1BCHEACHEALDH1A1CD274 | |
| SCHEMBL1327158 | 0.90 | C5AR1 (0.41) | C5AR1BCHEACHEHTTSMN1; SMN2 | |
| SCHEMBL1328543 | 0.89 | HTT (0.47) | C5AR1BCHEACHEHTTSMN1; SMN2 | |
| SCHEMBL1328511 | 0.89 | C5AR1 (0.45) | C5AR1BCHEACHEHTTSMN1; SMN2 | |
| SCHEMBL1328815 | 0.88 | HTT (0.46) | C5AR1BCHEACHEHTTSMN1; SMN2 | |
| SCHEMBL1329021 | 0.88 | BCHE (0.44) | C5AR1BCHEACHEHTTSMN1; SMN2 | |
| SCHEMBL1329162 | 0.87 | C5AR1 (0.43) | C5AR1BCHEACHEHTTSMN1; SMN2 | |
| SCHEMBL1328682 | 0.87 | BCHE (0.45) | C5AR1BCHEACHEHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863454-B2 | 3-substituted-6-aryl pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-01-04 | — | — | US | disclosed |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-07-09 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | C3AR1, C5AR1, C5AR2 | C5AR1 2/4885BCHE 3774/4885ACHE 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.